Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Macrolide Antibiotic
Original Date: 
December 2016
  • Treatment of infections due to susceptible organisms including Bordetella pertussis and Chlamydia trachomatis
  • IV intermittent infusion: over 1 hour
    • Intravenous administration should only be considered when oral therapy not suitable
  • PO


  • 10 mg/kg/dose once daily for 5 days
Side Effects: 
  • CVS: ventricular arrhythmia, prolongation of QTc interval, bradycardia
  • GI: diarrhea, vomiting, infantile hypertrophic stenosis (extremely rare)
  • Hematologic: anemia, leukopenia, thrombocytopenia
  • Hepatic: cholestatic hepatitis, jaundice, LFT's increased
  • Local: venous irritation, inflammation (with IV administration)
  • Renal: interstitial nephritis
Parameters to Monitor: 
  • Liver function tests
  • WBC with differential
  • Injection site
Reconstitution and Stability: 
  • Azithromycin 500 mg vial
    • Add 4.8 mL of SWFI
    • Take 1 mL (100 mg) and add to 49 mL D5W
    • Final concentration: 2 mg/mL*

* Infusion of Azithromycin with a concentration greater than 2 mg/mL will result in a local infusion site reaction and should be avoided.


- Solutions Compatible: D5W, 0.45%NaCl, 0.9%NaCl, D5W/0.45%NaCl, D5W/0.9%NaCl

- Y-site Compatible (when azithromycin is diluted in D5W): calcium gluconate, cefotaxime (up to 20 mg/mL), dobutamine, dopamine, epinephrine (up to 50 mcg/mL), fentanyl, gentamicin, heparin, morphine, potassium chloride, tobramycin

Incompatible: midazolam

  • Oral bioavailability of the oral suspension is increased by feeds

- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc;2015

- Pickering LK, ed 2012 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012

- American Society of Health-System Pharmacists (ASHP).  Handbook on Injectable Drugs. 19th Edition, Bethesda: ASHP 2017

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.